Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AAIPharma and CML Appoints CEO

Published: Thursday, July 10, 2014
Last Updated: Thursday, July 10, 2014
Bookmark and Share
Appointment of Stephan Kutzer as Chief Executive Officer, effective August 1, 2014.

AAIPharma Services Corp. and Cambridge Major Laboratories, Inc have announced the appointment of Stephan Kutzer, Ph.D. as Chief Executive Officer (CEO), effective August 1, 2014.

“Stephan brings valuable leadership experience with over 18 years’ in the pharmaceutical industry. His diverse background in operations, technical services, API development and manufacturing positions him well to take our company to the next level,” said Susan Nestegard, acting CEO.

Nestegard continued, “He will continue our focus on best in class safety, quality, and exceeding customer expectations to achieve our vision of being the Contract Manufacturing and Development Organization (CDMO) of first choice in the pharmaceutical sector.”

Most recently, Dr. Kutzer served as Chief Operating Officer of Lonza, Inc. (part of the Lonza Group, a Swiss chemicals and biotechnology company). Since 2003, he has also served as Chief Operating Officer and/or President of several divisions, including Lonza Pharma Biotech Division, Lonza Custom Manufacturing, Lonza Biopharmaceuticals and Lonza Performance Chemicals.

From 1999 to 2002, he served as Site Director and Vice President of Operations of Lonza’s Bayport, Texas facilities, and in 1999, he was Director of Process Improvement at Lonza Guangzhou Ltd. Guangzhou, PR China.

At Lonza Visp, he was Production and Plant Manager (1998) and Assistant Production Manager (1996) of Nicotinates. Dr. Kutzer holds a Master’s Degree in Chemical and Process Engineering and a Ph.D. in Engineering Sciences (Chemical Engineering) from the Technical University of Munich, Germany.

“AAIPharma and Cambridge Major Laboratories are highly regarded for their expertise in pharmaceutical development and manufacturing services for clients around the world. These companies offer the unique set of people, capabilities and continuum of services required to enhance and expedite pharmaceutical development globally,” said Dr. Kutzer. “I am excited to be part of this high growth company and talented team.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AAIPharma and CML Announce the Appointments of Vice Presidents
Appointment of Ted Dolan as Vice President, API Operations and Syed T. Husain as Vice President, API Business Unit.
Friday, October 10, 2014
AAIPharma and CML Announce Patrick Walsh’s Resignation as CEO
Both Companies announces the appointment of interim CEO, Susan Nestegard.
Saturday, April 12, 2014
Cambridge Major Laboratories and AAIPharma Services Announce Merger
Merger is expected to close by the end of October 2013.
Thursday, October 03, 2013
AAIPharma Expands Capacity of Parenteral Manufacturing Facility
Addition of on-site formulation development capabilities and enhanced analytical instrumentation.
Friday, December 28, 2012
AAIPharma Services Acquires Celsis Analytical Services
Combined company creates one of the leading material testing businesses offering a comprehensive range of testing services to numerous industries.
Monday, February 13, 2012
Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!